ul. Kukiełki 3A
02-207 Warszawa

+48 22 862 36 64
biuro@mededu.pl

Kategoria: OncoReview
Sortuj wg:
Domyślnie | Autor | Daty | Wyświetleń


OncoReview 2017; 1(25): 44-48

Autorzy: Marek Kowalczyk, Michał Piątek, Dorota Imielska-Zdunek, Aleksandra Derra, Aleksandra Zemła, Agnieszka Boratyn-Nowicka

Streszczenie: 

Abstract: This article presents methods of effective treatment of primary metastatic nasopharyngeal carcinoma, both causative and symptomatic, taking into account possible available treatment therapies(chemotherapy, targeted therapy, radiotherapy), and includes a case report. The applied treatment allowed for satisfactory control of the disease and much higher overall survival than expected – the patient survived for 53 months from the initial diagnosis and 41 months from being diagnosed with metastatic carcinoma.

Słowa kluczowe:

Key words: nasopharyngeal carcinoma, strategy of treatment, systemic therapy
Informacje o publikacji
Dodany 2017-09-05
DOI:
Wielkość 106.33 KB
Dodany przez Marcin Kuźma
Pobrany 331


OncoReview 2017; 1(25): 32-37

Autorzy: Maria Kurowska, Joanna Malicka, Jerzy S. Tarach

Streszczenie: 

Abstract: Introduction: Acromegaly in the course of a pituitary microadenoma or neuroendocrine GHRH-secreting tumour (GHRH, growth hormone-releasing hormone) MRI invisible is very rare. Objective: To present the difficulties in determining the cause behind an excessive production of the growth hormone in a patient suffering from long-standing acromegaly, without a pituitary focal lesion that would be visible on MRI. Case report: The authors describe a case of a 69-year-old female with acromegaly, diagnosed 22 yearsearlier based on the typical somatic symptoms, and confirmed by the elevated concentration of insulin-like growth factor type 1 and lack of growth hormone suppression in the oral glucose tolerancetest. The initial MRI scan (1994) had revealed a hypoechogenic 2 x 3 mm lesion in the anterior lobe ofthe pituitary gland, whose presence was not reported in the subsequent MRI tests. As ectopic GHRH orgrowth hormone secretion was suspected, a neuroendocrine tumour was searched for. The 47.7 × 54× 35.7 mm tumour, located in the thoracic outlet, accumulating tektreotide in receptor scintigraphy,turned out to be a nodular goitre on histopathology. Due to the undetermined location of the source of growth hormone overproduction, failure to measure GHRH levels, and the patient’s lack of consentto undergo sella turcica exploration, long-acting release octreotide had been used for many years tomanage the patient’s condition.Summary: The long-lasting and ineffective search for a neuroendocrine tumour producing GHRH orgrowth hormone as well as the absence of a focal lesion in the repeated MRI scans render it impossibleto unequivocally determine the cause of the patient’s acromegaly, and illustrate the difficulties indiscovering the source of growth hormone overproduction. Summary: The long-lasting and ineffective search for a neuroendocrine tumour producing GHRH or growth hormone as well as the absence of a focal lesion in the repeated MRI scans render it impossible to unequivocally determine the cause of the patient’s acromegaly, and illustrate the difficulties in discovering the source of growth hormone overproduction. Summary: The long-lasting and ineffective search for a neuroendocrine tumour producing GHRH orgrowth hormone as well as the absence of a focal lesion in the repeated MRI scans render it impossibleto unequivocally determine the cause of the patient’s acromegaly, and illustrate the difficulties indiscovering the source of growth hormone overproduction. Summary: The long-lasting and ineffective search for a neuroendocrine tumour producing GHRH or growth hormone as well as the absence of a focal lesion in the repeated MRI scans render it impossible to unequivocally determine the cause of the patient’s acromegaly, and illustrate the difficulties in discovering the source of growth hormone overproduction.

Słowa kluczowe:

Key words: acromegaly, microadenoma, neuroendocrine tumour, ectopic GHRH secretion
Informacje o publikacji
Dodany 2017-09-05
DOI:
Wielkość 152.95 KB
Dodany przez Marcin Kuźma
Pobrany 303


OncoReview 2017; 1(25): 22-27

Autorzy: Agnieszka Kolasińska-Ćwikła

Streszczenie: 

Abstract: Neuroendocrine tumours are a rare and heterogeneous group of neoplasms. Most of the patients are diagnosed with locally advanced or metastatic disease and curative surgery is rarely an option.Somatostatin analogues have been shown to control the symptoms and growth of well-differentiated metastatic neuroendocrine tumours. Octreotide LAR is one of the treatment options.

Słowa kluczowe:

Key words: neuroendocrine tumours, somatostatin analogues, octreotide LAR
Informacje o publikacji
Dodany 2017-09-05
DOI:
Wielkość 85.71 KB
Dodany przez Marcin Kuźma
Pobrany 276


OncoReview 2016; 4(24): 169-174

Autorzy: Jan Styczyński

Streszczenie: 

Abstract: This paper reports on diagnostic and therapeutic management of pulmonary invasive fungal disease (IFD) in a child with relapsed acute myeloid leukaemia, undergoing chemotherapy followed by haematopoietic stem cell transplantation. Surgical management with resection of the involved lung tissue was based on the location of fungal infiltrates close to large circulatory vessels. After examination of resected pulmonary tissue, a diagnosis of proven IFD was done. This case report is an example that aspergillosis is usually the cause for pulmonary IFD. Pharmacotherapy of pulmonary IFD should be based on compounds with good penetration to lung tissue: amphotericin B lipid form or voriconazole.

Słowa kluczowe:

Key words: invasive fungal disease, invasive fungal infection, pulmonary aspergillosis, chemotherapy, haematopoietic stem cell transplantation, amphotericin B lipid form
Informacje o publikacji
Dodany 2017-09-05
DOI:
Wielkość 564.62 KB
Dodany przez Marcin Kuźma
Pobrany 294


OncoReview 2016; 4(24): 162-168

Autorzy: Przemysław Witek, Marta Gutowska

Streszczenie: 

Abstract: Acromegaly is a rare disease, caused by growth hormone (GH) hypersecretion and secondarily elevated insulin-like growth factor1 (IGF-1) level. Nearly all patients with acromegaly suffer from somatotroph pituitary adenoma. The main goal of treatment is to normalise both GH and IGF-1 levels, which reduces symptoms, complications and mortality. Transsphenoidal selective adenomectomy performed by an experienced neurosurgeon is the first-line therapy. Therapy with somatostatin analogues (SSA) is used as a neoadjuvant treatment prior to surgery and in a persistent disease following the surgery.The long-acting somatostatin analogues reduce serum GH/IGF-1 levels and tumour volume. In this clinical review, mechanisms and role of 1st and 2nd generation somatostatin analogues in the treatment of patients with acromegaly are presented, with particular emphasis on the effects on somatotroph pituitary adenoma volume reduction.

Słowa kluczowe:

Key words: pasireotide, lanreotide, octreotide, long-acting somatostatin analogues, tumour volume reduction, insulin-like growth factor 1, growth hormone, acromegaly, somatotroph pituitary adenoma
Informacje o publikacji
Dodany 2017-09-05
DOI:
Wielkość 285.39 KB
Dodany przez Marcin Kuźma
Pobrany 283